BAJAJ BROKING

Notification close image
No new Notification messages
card image
Anondita Medicare IPO is Open!
Apply for the Anondita Medicare IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

531739

GENNEX

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GENNEX LABORATORIES LTD. Share Price Update

As of the latest trading session, GENNEX LABORATORIES LTD. share price is currently at ₹ 12.09, which is up by ₹ 0.15 from its previous closing. Today, the stock has fluctuated between ₹ 11.85 and ₹ 12.22. Over the past year, GENNEX LABORATORIES LTD. has achieved a return of -29.33 %. In the last month alone, the return has been -9.45 %. Read More...

Investment Returns

Over 1 Month -9.45% Over 3 Months -7.93% Over 6 Months -8.21% Over 1 Year -29.33%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GENNEX LABORATORIES LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    274.50

  • P/E Ratio (TTM)

    19.47

  • Beta

    0.93

  • Book Value / share

    7.87

  • Return on equity

    9.45%

  • EPS (TTM)

    0.62

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    4.15

info icon alternate text

GENNEX LABORATORIES LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 25.64
Operating Expense 23.05
Net Profit 4.15
Net Profit Margin (%) 16.18
Earnings Per Share (EPS) 0.18
EBITDA 5.64
Effective Tax Rate (%) 14.43
Particulars MAR 2025 (Values in Cr)
Revenue 23.28
Operating Expense 23.82
Net Profit 1.50
Net Profit Margin (%) 6.44
Earnings Per Share (EPS) 0.07
EBITDA 2.94
Effective Tax Rate (%) 30.73
Particulars DEC 2024 (Values in Cr)
Revenue 25.28
Operating Expense 22.39
Net Profit 4.21
Net Profit Margin (%) 16.65
Earnings Per Share (EPS) 0.19
EBITDA 5.57
Effective Tax Rate (%) 15.12
Particulars SEP 2024 (Values in Cr)
Revenue 24.69
Operating Expense 21.50
Net Profit 4.16
Net Profit Margin (%) 16.84
Earnings Per Share (EPS) 0.18
EBITDA 5.52
Effective Tax Rate (%) 16.96
Particulars JUN 2024 (Values in Cr)
Revenue 21.33
Operating Expense 18.86
Net Profit 4.17
Net Profit Margin (%) 19.54
Earnings Per Share (EPS) 0.18
EBITDA 5.38
Effective Tax Rate (%) 15.24
Particulars MAR 2025 (Values in Cr)
Revenue 94.58
Operating Expense 86.58
Net Profit 14.04
Net Profit Margin (%) 14.84
Earnings Per Share (EPS) 0.62
EBITDA 19.41
Effective Tax Rate (%) 17.70
Particulars MAR 2024 (Values in Cr)
Revenue 86.71
Operating Expense 75.13
Net Profit 13.18
Net Profit Margin (%) 15.20
Earnings Per Share (EPS) 0.70
EBITDA 21.94
Effective Tax Rate (%) 20.13
Particulars MAR 2023 (Values in Cr)
Revenue 65.10
Operating Expense 62.48
Net Profit 4.56
Net Profit Margin (%) 7.00
Earnings Per Share (EPS) 0.26
EBITDA 7.98
Effective Tax Rate (%) 24.12
Particulars MAR 2022 (Values in Cr)
Revenue 61.21
Operating Expense 57.50
Net Profit 3.92
Net Profit Margin (%) 6.40
Earnings Per Share (EPS) 0.33
EBITDA 6.76
Effective Tax Rate (%) 22.98
Particulars MAR 2021 (Values in Cr)
Revenue 59.65
Operating Expense 54.74
Net Profit 4.04
Net Profit Margin (%) 6.77
Earnings Per Share (EPS) 0.32
EBITDA 6.68
Effective Tax Rate (%) 20.15
Particulars MAR 2024 (Values in Cr)
Book Value / Share 7.24
ROE % 10.51
ROCE % 13.64
Total Debt to Total Equity 0.03
EBITDA Margin 22.31
Particulars MAR 2023 (Values in Cr)
Book Value / Share 4.46
ROE % 7.91
ROCE % 10.17
Total Debt to Total Equity 0.09
EBITDA Margin 12.02
Particulars MAR 2022 (Values in Cr)
Book Value / Share 3.46
ROE % 9.35
ROCE % 11.78
Total Debt to Total Equity 0.21
EBITDA Margin 10.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3.14
ROE % 10.67
ROCE % 13.16
Total Debt to Total Equity 0.16
EBITDA Margin 10.49
Particulars MAR 2020 (Values in Cr)
Book Value / Share 2.82
ROE % 5.34
ROCE % 8.33
Total Debt to Total Equity 0.14
EBITDA Margin 7.17
Particulars MAR 2024 (Values in Cr)
Book Value / Share 7.26
ROE % 9.45
ROCE % 12.50
Total Debt to Total Equity 0.01
EBITDA Margin 22.59
Particulars MAR 2023 (Values in Cr)
Book Value / Share 4.39
ROE % 7.41
ROCE % 10.69
Total Debt to Total Equity 0.09
EBITDA Margin 11.20
Particulars MAR 2022 (Values in Cr)
Book Value / Share 3.48
ROE % 9.35
ROCE % 11.78
Total Debt to Total Equity 0.21
EBITDA Margin 10.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 3.15
ROE % 10.67
ROCE % 13.17
Total Debt to Total Equity 0.16
EBITDA Margin 10.49
Particulars MAR 2020 (Values in Cr)
Book Value / Share 2.83
ROE % 5.33
ROCE % 8.31
Total Debt to Total Equity 0.14
EBITDA Margin 7.17
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 60.97
Total Assets 229.98
Total Liabilities 229.98
Total Equity 176.46
Share Outstanding 227447674
Price to Book Ratio 2.18
Return on Assets (%) 5.72
Return on Capital (%) 7.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 15.06
Total Assets 132.31
Total Liabilities 132.31
Total Equity 86.51
Share Outstanding 180192662
Price to Book Ratio 1.28
Return on Assets (%) 3.71
Return on Capital (%) 5.62
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.31
Total Assets 68.02
Total Liabilities 68.02
Total Equity 43.81
Share Outstanding 126503000
Price to Book Ratio 2.16
Return on Assets (%) 5.76
Return on Capital (%) 7.27
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.06
Total Assets 58.90
Total Liabilities 58.90
Total Equity 39.70
Share Outstanding 126503000
Price to Book Ratio 1.24
Return on Assets (%) 6.85
Return on Capital (%) 8.58
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.91
Total Assets 56.94
Total Liabilities 56.94
Total Equity 35.67
Share Outstanding 126503000
Price to Book Ratio 0.66
Return on Assets (%) 3.25
Return on Capital (%) 4.57
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 60.96
Total Assets 205.33
Total Liabilities 205.33
Total Equity 170.75
Share Outstanding 227447674
Price to Book Ratio 2.18
Return on Assets (%) 5.74
Return on Capital (%) 6.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 14.45
Total Assets 96.22
Total Liabilities 96.22
Total Equity 79.01
Share Outstanding 180192661
Price to Book Ratio 1.28
Return on Assets (%) 4.73
Return on Capital (%) 5.7
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 8.31
Total Assets 68.20
Total Liabilities 68.20
Total Equity 43.99
Share Outstanding 126503000
Price to Book Ratio 2.16
Return on Assets (%) 5.75
Return on Capital (%) 7.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.06
Total Assets 59.08
Total Liabilities 59.08
Total Equity 39.89
Share Outstanding 126503000
Price to Book Ratio 1.24
Return on Assets (%) 6.83
Return on Capital (%) 8.55
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.91
Total Assets 57.12
Total Liabilities 57.12
Total Equity 35.85
Share Outstanding 126503000
Price to Book Ratio 0.66
Return on Assets (%) 3.24
Return on Capital (%) 4.55
Particulars MAR 2024 (Values in Cr)
Net Income 16.49
Cash from Operations -46.68
Cash from Investing 18.91
Cash from Financing 73.68
Net change in Cash 45.91
Free Cash Flow -46.68
Particulars MAR 2023 (Values in Cr)
Net Income 6.37
Cash from Operations 23.67
Cash from Investing -38.32
Cash from Financing 21.03
Net change in Cash 6.38
Free Cash Flow 63.46
Particulars MAR 2022 (Values in Cr)
Net Income 5.27
Cash from Operations 13.01
Cash from Investing -2.46
Cash from Financing -1.83
Net change in Cash 7.61
Free Cash Flow 14.61
Particulars MAR 2021 (Values in Cr)
Net Income 5.06
Cash from Operations 0.09
Cash from Investing -0.02
Cash from Financing 1.61
Net change in Cash 0.15
Free Cash Flow 0.17
Particulars MAR 2020 (Values in Cr)
Net Income 2.54
Cash from Operations -1.66
Cash from Investing -0.21
Cash from Financing -0.34
Net change in Cash -2.23
Free Cash Flow -1.37
Particulars MAR 2024 (Values in Cr)
Net Income 14.86
Cash from Operations -32.33
Cash from Investing 0.92
Cash from Financing 79.01
Net change in Cash 46.51
Free Cash Flow -29.49
Particulars MAR 2023 (Values in Cr)
Net Income 6.01
Cash from Operations -14.45
Cash from Investing -0.76
Cash from Financing 21.35
Net change in Cash 6.13
Free Cash Flow -12.22
Particulars MAR 2022 (Values in Cr)
Net Income 5.27
Cash from Operations 7.74
Cash from Investing -1.26
Cash from Financing 1.86
Net change in Cash 7.24
Free Cash Flow 8.13
Particulars MAR 2021 (Values in Cr)
Net Income 5.06
Cash from Operations 0.09
Cash from Investing -0.02
Cash from Financing 1.61
Net change in Cash 0.15
Free Cash Flow 0.17
Particulars MAR 2020 (Values in Cr)
Net Income 2.54
Cash from Operations -1.66
Cash from Investing -0.21
Cash from Financing -0.34
Net change in Cash -2.23
Free Cash Flow -1.37
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 34.33 14.01 1.87 263.08 30.00 / 69.75
BLISS GVS PHARMA LTD 161.45 15.97 1.62 1703.26 105.05 / 190.65
CIPLA LTD 1592.30 23.85 4.12 128618.68 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 336.10 9.46 2.72 989.18 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 34.33 18.66 5.42 263.08 30.00 / 69.75
AMRUTAJAN HEALTH LTD 701.35 37.19 6.20 2027.65 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8431.65 99.68 27.36 21079.13 6222.35 / 10653.05
BLISS GVS PHARMA LTD 161.45 24.13 1.60 1703.26 105.05 / 190.65

GENNEX LABORATORIES LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
12.07 1.17 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 12.10
  • 26 Days 12.50
  • 10 Days 12.20
  • 50 Days 12.80
  • 12 Days 12.30
  • 100 Days 13.20
  • 20 Days 12.40
  • 200 Days 14.20
12.01 PIVOT

First Support

11.72

First Resistance

12.21

Second Support

11.52

Second Resistance

12.50

Third Support

11.23

Third Resistance

12.70

RSI

42.06

ADX

84.75

MACD

-0.27

Williams % R

-62.84

Commodity Channel Index (CCI)

-106.54

Date

2025-08-22

Week

396750.00

Same Day

524560.00

Month

322054.00

1 Year

0.94

3 Year

0.51

Over 1 Month

-9.45%

down

Over 1 Year

-29.33%

down

Over 3 Months

-7.93%

down

Over 3 Years

20.54%

down

Over 6 Months

-8.21%

down

Over 5 Years

23.50%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

GENNEX LABORATORIES LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

GENNEX LABORATORIES LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
14 Dec 2009 10.0 1.0 15 Dec 2009

GENNEX LABORATORIES LTD. Share Price

Gennex Laboratories Limited (formerly Prudential Pharmaceuticals Limited) was incorporated on June 25, 1985. The Company got converted into a Public Limited Company and the name was changed from Prudential Pharmaceuticals Limited to Gennex Laboratories Limited in 2007.

The Company is one of the leading manufacturers and exporters of Active pharmaceutical ingredients and Intermediates. It is engaged in manufacturing and marketing of bulk drugs and intermediates.

Gennex is among the leading Vertically Integrated' pharmaceutical companies in India and has a robust product portfolio spread over major product segments encompassing Expectorants, Muscle Relaxants, Analgesic and Anti Fungal. The company thrives on the strength of its exports to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and Others. The Company's factory is situated at Andhra Pradesh, India. The company has a professionally managed team at every stage of its operations.

During the year 2005-2006, the company implemented GMP (Good Manufacturing Practices). In 2006-07, it installed Separate Air Handling System in final drug isolation area and also in drying and packing area. Also, it implemented the CGMP in manufacturing area as per ICH & WHO Guidelines. In 2007-2008, it diversified into the business of Biotech product.

The Company acquired 51% shareholding in Deccan Remedies Limited and thus became the subsidiary of the Company in 2023.

Parent organization Prudential
NSE symbol [-]
Founded 1990
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Gennex Laboratories Ltd?

Answer Field

Gennex Laboratories Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 12.07 as on Aug 22 2025 03:28 PM.

What is the Market Cap of Gennex Laboratories Ltd Share?

Answer Field

The market cap of Gennex Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 274.50 as on Aug 22 2025 03:28 PM.

What is the 52 Week High and Low of Gennex Laboratories Ltd?

Answer Field

The 52 Week High and Low of Gennex Laboratories Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 29.00 and ₹ 11.15.

What is 1 year return for Gennex Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been -29.33%.

What is the P/E Ratio of Gennex Laboratories Ltd Share?

Answer Field

As on Aug 22 2025 03:28 PM the price-to-earnings (PE) ratio for Gennex Laboratories Ltd share is 19.47.

What is the PB ratio of Gennex Laboratories Ltd Share?

Answer Field

As on Aug 22 2025 03:28 PM, the price-to-book (PB) ratio for Gennex Laboratories Ltd share is 7.87.

How to Buy Gennex Laboratories Ltd Share?

Answer Field

You can trade in Gennex Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Gennex Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Gennex Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Gennex Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91